NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
VKTX
Viking Therapeutics, Inc.
There isn't enough reported data to score VKTX yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
VKTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
VKTX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
VKTX PE Valuation
VKTX has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
VKTX Forward outlook
There aren't enough analyst estimates for VKTX to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over VKTX on earnings quality, reporting a profit while its opponent remains loss making.
VKTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.41 | -$3.28 |
| Q2 2026 | -$4.67 | -$3.13 |
| Q1 2026 | -$4.15 | -$2.99 |
| Q4 2025 | -$3.19 | -$2.18 |
| Q3 2025 | -$2.13 | -$1.21 |
| Q2 2025 | -$1.54 | -$0.61 |
| Q1 2025 | -$1.16 | -$0.24 |
| Q4 2024 | -$1.01 | -$0.10 |
VKTX lost $5.41 per share over the past year, and its loss has widened in each of the last eight quarters.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over VKTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
VKTX Quarterly Revenue
VKTX's revenue is shrinking: $0 last quarter.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over VKTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
VKTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$138.2M | -$44.2M |
| Q2 2026 | -$125.2M | -$78.1M |
| Q1 2026 | -$114M | -$61.6M |
| Q4 2025 | -$85.3M | -$54.1M |
| Q3 2025 | -$94M | -$72M |
| Q2 2025 | -$47.1M | -$18.5M |
| Q1 2025 | -$52.3M | -$46.2M |
| Q4 2024 | -$31.2M | -$13.5M |
VKTX has burned cash in almost every quarter: −$463M over the past year, against −$225M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over VKTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
VKTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +1.8M shares |
| 1 year | +5.1% | +5.7M shares |
| 3 years | +18% | +18.2M shares |
| 5 years | +51% | +40M shares |
| Available history | +64% | +46.1M shares |
VKTX has 118M diluted shares, up 5.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $1.7M |
| Q1 2022 | $5.1M |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
VKTX Net Leverage
VKTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
VKTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.7 | Neutral |
| Stochastic | 17.7 | Oversold |
VKTX's weekly RSI is 45 (neutral) and its Stochastic is 18 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
VKTX PE vs Healthcare Sector
VKTX has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over VKTX on trend strength, trading above more of its moving averages.
VKTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.2 | 2.1% below |
| 20 week MA | $31.7 | 13% below |
| 50 week MA | $32.4 | 15% below |
| 100 week MA | $31.7 | 13% below |
| 200 week MA | $33.9 | 19% below |
VKTX is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over VKTX on returns for 2026, with the stronger performance.
VKTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.33 | $6.20 | -26% |
| 2021 | $6.20 | $5.18 | -16% |
| 2022 | $5.18 | $8.45 | +63% |
| 2023 | $8.45 | $18.6 | +120% |
| 2024 | $18.6 | $41.2 | +121% |
| 2025 | $41.2 | $37.2 | -9.7% |
| 2026 YTD | $37.2 | $27.6 | -26% |
VKTX has finished lower in three of the last six years. It's down 26% so far in 2026.